{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:09:11Z","timestamp":1792202951472,"version":"4.4.0"},"update-to":[{"DOI":"10.1002\/14651858.cd014769","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000}}],"reference-count":161,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd014769.pub2","type":"journal-article","created":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T06:53:34Z","timestamp":1730789614000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Statins for the primary prevention of venous thromboembolism"],"prefix":"10.1002","volume":"2024","author":[{"given":"Zixin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery; The Second Xiangya Hospital, Central South University; Changsha China"},{"name":"Clinical Research Center for Breast Disease; Hunan Province; Changsha China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pediatric Surgery; The Second Hospital of Nanyang City; Nanyang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhui","family":"Tian","sequence":"additional","affiliation":[{"name":"Evidence-Based Medicine Center, School of Basic Medical Sciences; Lanzhou University; Lanzhou City China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peizhen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Maternity and Child-care; Hospital of Lanzhou City; Lanzhou City China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kehu","family":"Yang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu Province; Lanzhou University; Lanzhou City China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery; The Second Xiangya Hospital, Central South University; Changsha China"},{"name":"Clinical Research Center for Breast Disease; Hunan Province; Changsha China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,11,5]]},"reference":[{"issue":"6","key":"10.1002\/14651858.CD014769.pub2-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1111\/jth.14004","article-title":"Effect of rosuvastatin on risk markers for venous thromboembolism in cancer","volume":"16","author":"Ades","year":"2018","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"6","key":"10.1002\/14651858.CD014769.pub2-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1056\/NEJMoa061894","article-title":"High-dose atorvastatin after stroke or transient ischemic attack","volume":"355","author":"Amarenco","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"18","key":"10.1002\/14651858.CD014769.pub2-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1161\/01.CIR.0000146378.65439.7A","article-title":"Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria","volume":"110","author":"Asselbergs","year":"2004","journal-title":"Circulation"},{"issue":"2","key":"10.1002\/14651858.CD014769.pub2-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1161\/CIRCULATIONAHA.109.900027","article-title":"Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial","volume":"121","author":"Chan","year":"2010","journal-title":"Circulation"},{"issue":"6","key":"10.1002\/14651858.CD014769.pub2-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.ahj.2007.03.011","article-title":"Rationale, design, and baseline characteristics of a randomized trial to assess the effect of cholesterol lowering on the progression of aortic stenosis: the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) trial","volume":"153","author":"Chan","year":"2007","journal-title":"American Heart Journal"},{"issue":"9435","key":"10.1002\/14651858.CD014769.pub2-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD014769.pub2-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1046\/j.1464-5491.2002.00643.x","article-title":"Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes","volume":"19","author":"Colhoun","year":"2002","journal-title":"Diabetic Medicine"},{"issue":"23","key":"10.1002\/14651858.CD014769.pub2-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1056\/NEJMoa043876","article-title":"A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis","volume":"352","author":"Cowell","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD014769.pub2-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1023\/B:CARD.0000033645.55138.3d","article-title":"Measuring effects on intima media thickness: an evaluation of rosuvastatin in subclinical atherosclerosis - the rationale and methodology of the METEOR study","volume":"18","author":"Grobbee","year":"2004","journal-title":"Cardiovascular Drugs and Therapy"},{"issue":"12","key":"10.1002\/14651858.CD014769.pub2-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1001\/jama.297.12.1344","article-title":"Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial","volume":"297","author":"Raichlen","year":"2007","journal-title":"Journal of the American Medical Association"},{"issue":"5","key":"10.1002\/14651858.CD014769.pub2-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1136\/thoraxjnl-2015-208017","article-title":"One-year outcomes of rosuvastatin versus placebo in sepsis-associated acute respiratory distress syndrome: prospective follow-up of SAILS randomised trial","volume":"71","author":"Dinglas","year":"2016","journal-title":"Thorax"},{"issue":"23","key":"10.1002\/14651858.CD014769.pub2-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1056\/NEJMoa1401520","article-title":"Rosuvastatin for sepsis-associated acute respiratory distress syndrome","volume":"370","author":"Truwit","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD014769.pub2-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/s0002-9149(97)00347-0","article-title":"Design and rationale of the Air Force\/Texas Coronary Atherosclerosis Prevention Study (AFCAPS\/TexCAPS)","volume":"80","author":"Downs","year":"1997","journal-title":"American Journal of Cardiology"},{"issue":"20","key":"10.1002\/14651858.CD014769.pub2-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS (Air Force\/Texas Coronary Atherosclerosis Prevention Study)","volume":"279","author":"Downs","year":"1998","journal-title":"Journal of the American Medical Association"},{"issue":"1","key":"10.1002\/14651858.CD014769.pub2-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.atherosclerosis.2010.07.053","article-title":"Effect of atorvastatin on kidney function in chronic kidney disease: a randomised double-blind placebo-controlled trial","volume":"213","author":"Fassett","year":"2010","journal-title":"Atherosclerosis"},{"issue":"12","key":"10.1002\/14651858.CD014769.pub2-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1212\/WNL.0b013e3181d6476a","article-title":"Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe","volume":"74","author":"Feldman","year":"2010","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/14651858.CD014769.pub2-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jalz.2008.02.001","article-title":"The Atorvastatin\/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics","volume":"4","author":"Jones","year":"2008","journal-title":"Alzheimer's & Dementia"},{"issue":"4","key":"10.1002\/14651858.CD014769.pub2-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1111\/j.1523-1755.2004.00919.x","article-title":"Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial","volume":"66","author":"Fellstr\u00f6m","year":"2004","journal-title":"Kidney International"},{"issue":"9374","key":"10.1002\/14651858.CD014769.pub2-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1016\/S0140-6736(03)13638-0","article-title":"Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial","volume":"361","author":"Holdaas","year":"2003","journal-title":"Lancet"},{"issue":"14","key":"10.1002\/14651858.CD014769.pub2-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstr\u00f6m","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD014769.pub2-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1471-2318-11-8","article-title":"Incident venous thromboembolic events in the prospective study of pravastatin in the elderly at risk (PROSPER)","volume":"11","author":"Freeman","year":"2011","journal-title":"BMC Geriatrics"},{"issue":"1","key":"10.1002\/14651858.CD014769.pub2-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1161\/CIRCULATIONAHA.109.874834","article-title":"Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER)","volume":"121","author":"Everett","year":"2010","journal-title":"Circulation"},{"issue":"9","key":"10.1002\/14651858.CD014769.pub2-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1586\/erc.09.93","article-title":"Primary prevention of vascular events in patients with high levels of C-reactive protein: the JUPITER study","volume":"7","author":"Fonseca","year":"2009","journal-title":"Expert Review of Cardiovascular Therapy"},{"issue":"18","key":"10.1002\/14651858.CD014769.pub2-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1056\/NEJMoa0900241","article-title":"A randomized trial of rosuvastatin in the prevention of venous thromboembolism","volume":"360","author":"Glynn","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD014769.pub2-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"488","DOI":"10.7326\/0003-4819-152-8-201004200-00005","article-title":"Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial","volume":"152","author":"Glynn","year":"2010","journal-title":"Annals of Internal Medicine"},{"issue":"16","key":"10.1002\/14651858.CD014769.pub2-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1016\/j.jacc.2010.09.082","article-title":"Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg\/dl with rosuvastatin. The JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin)","volume":"57","author":"Hsia","year":"2011","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD014769.pub2-BIB0027|cit27","first-page":"104","article-title":"A randomised study of efficacy of statins in the prevention of venous thromboembolism","volume":"43","author":"Kerst","year":"2009","journal-title":"Geneesmiddelenbulletin"},{"issue":"1","key":"10.1002\/14651858.CD014769.pub2-BIB0028|cit28","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/eurheartj\/ehq370","article-title":"Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk >\/= 5% or Framingham risk >20%: post hoc analyses of the JUPITER trial requested by European health authorities","volume":"32","author":"Koenig","year":"2011","journal-title":"European Heart Journal"},{"issue":"9","key":"10.1002\/14651858.CD014769.pub2-BIB0029|cit29","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1161\/CIRCULATIONAHA.109.906479","article-title":"Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials","volume":"121","author":"Mora","year":"2010","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD014769.pub2-BIB0030|cit30","unstructured":"A randomized, double-blind, placebo controlled, multicenter, phase 3 study of rosuvastatin (CRESTOR\u00ae) 20 mg in the prevention of cardiovascular events among subjects with low levels of LDL cholesterol and elevated levels of C-reactive protein clinicaltrials.gov\/ct2\/show\/NCT00239681"},{"key":"10.1002\/14651858.CD014769.pub2-BIB0031|cit31","unstructured":"Ridker PM Danielson E Fonseca F Genest J Gotto AM Kastelein JJ Rosuvastatin in the prevention of cardiovascular events among 17,802 men and women with elevated levels of C-reactive protein: the JUPITER trial Circulation 2008 2310 10.1161\/CIRCULATIONAHA.108.191458"},{"issue":"9670","key":"10.1002\/14651858.CD014769.pub2-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/S0140-6736(09)60447-5","article-title":"Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial","volume":"373","author":"Ridker","year":"2009","journal-title":"Lancet"},{"issue":"21","key":"10.1002\/14651858.CD014769.pub2-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD014769.pub2-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1016\/j.amjcard.2007.09.072","article-title":"Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein","volume":"100","author":"Ridker","year":"2007","journal-title":"American Journal of Cardiology"},{"issue":"9738","key":"10.1002\/14651858.CD014769.pub2-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S0140-6736(10)60713-1","article-title":"HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial","volume":"376","author":"Ridker","year":"2010","journal-title":"Lancet"},{"issue":"12","key":"10.1002\/14651858.CD014769.pub2-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/j.jacc.2010.01.020","article-title":"Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial","volume":"55","author":"Ridker","year":"2010","journal-title":"American Journal of Cardiology"},{"issue":"6","key":"10.1002\/14651858.CD014769.pub2-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1161\/CIRCOUTCOMES.109.848473","article-title":"Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER)","volume":"2","author":"Ridker","year":"2009","journal-title":"Circulation: Cardiovascular Quality and Outcomes"},{"issue":"5","key":"10.1002\/14651858.CD014769.pub2-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1161\/CIRCOUTCOMES.110.938118","article-title":"Rosuvastatin for primary prevention among individuals with elevated high-sensitivity C-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for 'intermediate risk'","volume":"3","author":"Ridker","year":"2010","journal-title":"Circulation: Cardiovascular Quality and Outcomes"},{"issue":"9841","key":"10.1002\/14651858.CD014769.pub2-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(12)61190-8","article-title":"Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial","volume":"380","author":"Ridker","year":"2012","journal-title":"Lancet"},{"issue":"19","key":"10.1002\/14651858.CD014769.pub2-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1161\/01.CIR.0000100688.17280.E6","article-title":"Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial","volume":"108","author":"Ridker","year":"2003","journal-title":"Circulation"},{"issue":"10","key":"10.1002\/14651858.CD014769.pub2-BIB0041|cit41","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1185\/03007995.2010.516994","article-title":"Cost-effectiveness of statin therapy for vascular event prevention in adults with elevated C-reactive protein: implications of JUPITER","volume":"26","author":"Slejko","year":"2010","journal-title":"Current Medical Research and Opinion"},{"issue":"9326","key":"10.1002\/14651858.CD014769.pub2-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","author":"Heart Protection Study Collaborative Group","year":"2002","journal-title":"Lancet"},{"issue":"22","key":"10.1002\/14651858.CD014769.pub2-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","article-title":"Rosuvastatin in older patients with systolic heart failure","volume":"357","author":"Kjekshus","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD014769.pub2-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.2337\/dc05-2415","article-title":"Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN)","volume":"29","author":"Knopp","year":"2006","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1002\/14651858.CD014769.pub2-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1016\/j.jacc.2004.07.053","article-title":"Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study","volume":"44","author":"Koren","year":"2004","journal-title":"Journal of the American College of Cardiology"},{"issue":"19","key":"10.1002\/14651858.CD014769.pub2-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels","volume":"339","author":"Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group","year":"1998","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD014769.pub2-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1253\/circj.68.860","article-title":"Design and baseline characteristics of a study of primary prevention of coronary events with pravastatin among Japanese with mildly elevated cholesterol levels","volume":"68","author":"Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) study group","year":"2004","journal-title":"Circulation Journal"},{"issue":"9542","key":"10.1002\/14651858.CD014769.pub2-BIB0048|cit48","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/S0140-6736(06)69472-5","article-title":"Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial","volume":"368","author":"Nakamura","year":"2006","journal-title":"Lancet"},{"issue":"10088","key":"10.1002\/14651858.CD014769.pub2-BIB0049|cit49","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1016\/S0140-6736(17)31075-9","article-title":"Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase","volume":"389","author":"Gupta","year":"2017","journal-title":"Lancet"},{"issue":"9364","key":"10.1002\/14651858.CD014769.pub2-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","article-title":"Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD014769.pub2-BIB0051|cit51","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.jacc.2005.06.088","article-title":"Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure","volume":"47","author":"Sola","year":"2006","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD014769.pub2-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"e068407","DOI":"10.1136\/bmj-2021-068407","article-title":"Atorvastatin versus placebo in patients with covid-19 in intensive care: randomized controlled trial","volume":"376","author":"INSPIRATION-S Investigators","year":"2022","journal-title":"BMJ"},{"issue":"7","key":"10.1002\/14651858.CD014769.pub2-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1055\/a-2059-4844","article-title":"Atorvastatin versus placebo in ICU patients with COVID-19: ninety-day results of the INSPIRATION-S trial","volume":"123","author":"Talasaz","year":"2023","journal-title":"Thrombosis and Haemostasis"},{"issue":"9645","key":"10.1002\/14651858.CD014769.pub2-BIB0054|cit54","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/S0140-6736(08)61240-4","article-title":"Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Tavazzi","year":"2008","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD014769.pub2-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"21","key":"10.1002\/14651858.CD014769.pub2-BIB0056|cit56","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1056\/NEJMoa1600176","article-title":"Cholesterol lowering in intermediate-risk persons without cardiovascular disease","volume":"374","author":"Yusuf","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD014769.pub2-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1097\/MBC.0000000000001258","article-title":"Combination of aspirin and rosuvastatin for reduction of venous thromboembolism in severely injured patients: a double-blind, placebo-controlled, pragmatic randomized phase II clinical trial (The STAT Trial)","volume":"34","author":"Barrett","year":"2023","journal-title":"Blood Coagulation & Fibrinolysis"},{"issue":"1","key":"10.1002\/14651858.CD014769.pub2-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/jth.15537","article-title":"Statins for venous event reduction in patients with venous thromboembolism: a multicenter randomized controlled pilot trial assessing feasibility","volume":"20","author":"Delluc","year":"2022","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"2","key":"10.1002\/14651858.CD014769.pub2-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/jth.14364","article-title":"Rosuvastatin use reduces thrombin generation potential in patients with venous thromboembolism: a randomized controlled trial","volume":"17","author":"Orsi","year":"2019","journal-title":"Journal of Thrombosis & Haemostatis"},{"key":"10.1002\/14651858.CD014769.pub2-BIB0060|cit60","unstructured":"A randomized controlled trial of rosuvastatin in the prevention of deep vein thrombosis in total knee arthroplasty trialsearch.who.int\/Trial2.aspx?TrialID=ChiCTR2100048407"},{"key":"10.1002\/14651858.CD014769.pub2-BIB0061|cit61","unstructured":"High-dose periop statins for prevention of DVT clinicaltrials.gov\/show\/NCT00259662"},{"key":"10.1002\/14651858.CD014769.pub2-BIB0062|cit62","unstructured":"Rosuvastatin for preventing deep vein thrombosis (STOP-DVT) clinicaltrials.gov\/ct2\/show\/results\/NCT01021488"},{"issue":"5","key":"10.1002\/14651858.CD014769.pub2-BIB0063|cit63","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.cct.2011.06.001","article-title":"Rationale and design of STOP DVT study: rosuvastatin for the prevention of deep vein thrombosis in patients undergoing total knee replacement arthroplasty - a prospective randomized open-label controlled trial","volume":"32","author":"Park","year":"2011","journal-title":"Contemporary Clinical Trials"},{"key":"10.1002\/14651858.CD014769.pub2-BIB0064|cit64","unstructured":"Re-STOP DVT: reload of high dose atorvastatin for preventing deep vein thrombosis in statin users clinicaltrials.gov\/ct2\/show\/NCT01063426"},{"key":"10.1002\/14651858.CD014769.pub2-BIB0065|cit65","unstructured":"Detecting the impact of statin therapy on lowering risk of venous thrombo-embolic events (DISOLVE) clinicaltrials.gov\/ct2\/show\/NCT01524653"},{"key":"10.1002\/14651858.CD014769.pub2-BIB0066|cit66","unstructured":"Anti-platelet and statin therapy to prevent cancer-associated thrombosis clinicaltrials.gov\/show\/NCT02285738"},{"key":"10.1002\/14651858.CD014769.pub2-BIB0067|cit67","unstructured":"Pilot study of rosuvastatin and enoxaparin thromboprophylaxis following ovarian cancer surgery (O-STAT Study) clinicaltrials.gov\/show\/NCT03532139"},{"issue":"6","key":"10.1002\/14651858.CD014769.pub2-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1111\/jth.12223","article-title":"Statin therapy and levels of hemostatic factors in a healthy population: the multi-ethnic study of atherosclerosis","volume":"11","author":"Adams","year":"2013","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"10","key":"10.1002\/14651858.CD014769.pub2-BIB0069|cit69","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1111\/j.1742-1241.2010.02439.x","article-title":"Statin use and the prevention of venous thromboembolism: a meta-analysis","volume":"64","author":"Agarwal","year":"2010","journal-title":"International Journal of Clinical Practice"},{"key":"10.1002\/14651858.CD014769.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/2050-6511-14-57","article-title":"The association between statin therapy during intensive care unit stay and the incidence of venous thromboembolism: a propensity score-adjusted analysis","volume":"14","author":"Al Harbi","year":"2013","journal-title":"BMC pharmacology & toxicology"},{"issue":"1","key":"10.1002\/14651858.CD014769.pub2-BIB0071|cit71","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1001\/jama.286.1.64","article-title":"Effect of statin therapy on C-reactive protein levels: the pravastatin Inflammation\/CRP Evaluation (PRINCE): a randomized trial and cohort study","volume":"286","author":"Albert","year":"2001","journal-title":"Journal of the American Medical Association"},{"issue":"8","key":"10.1002\/14651858.CD014769.pub2-BIB0072|cit72","doi-asserted-by":"publisher","first-page":"879.e19","DOI":"10.1016\/j.amjmed.2016.01.041","article-title":"Secular trends in incidence and mortality of acute venous thromboembolism: the AB-VTE population-based study","volume":"129","author":"Alotaibi","year":"2016","journal-title":"American Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD014769.pub2-BIB0073|cit73","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/s0735-1097(00)00804-4","article-title":"Myocardial infarction redefined - a consensus document of The Joint European Society of Cardiology\/American College of Cardiology Committee for the redefinition of myocardial infarction","volume":"36","author":"Alpert","year":"2000","journal-title":"Journal of the American College of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD014769.pub2-BIB0074|cit74","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s10654-017-0238-y","article-title":"Time trends in incidence rates of venous thromboembolism in a large cohort recruited from the general population","volume":"32","author":"Arshad","year":"2017","journal-title":"European Journal of Epidemiology"},{"issue":"7454","key":"10.1002\/14651858.CD014769.pub2-BIB0075|cit75","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"issue":"7","key":"10.1002\/14651858.CD014769.pub2-BIB0076|cit76","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1111\/jth.13343","article-title":"Platelet reactivity in patients with venous thrombosis who use rosuvastatin: a randomized controlled clinical trial","volume":"14","author":"Biedermann","year":"2016","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014769.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/B978-1-4377-1720-4.00565-3","volume-title":"Essence of Anesthesia Practice","author":"Billings","year":"2011"},{"issue":"6","key":"10.1002\/14651858.CD014769.pub2-BIB0078|cit78","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007469.pub2","article-title":"Vitamin D supplementation for prevention of cancer in adults","author":"Bjelakovic","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD014769.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jclinepi.2007.10.007","article-title":"Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses","volume":"61","author":"Brok","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"issue":"1-2","key":"10.1002\/14651858.CD014769.pub2-BIB0080|cit80","first-page":"36","article-title":"Venous thromboembolism - management in general practice","volume":"38","author":"Chapman","year":"2009","journal-title":"Australian Family Physician"},{"issue":"Supp1","key":"10.1002\/14651858.CD014769.pub2-BIB0081|cit81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/00325481.2021.1955541","article-title":"Current issues in venous thromboembolism","volume":"133","author":"Cohen","year":"2021","journal-title":"Postgraduate Medicine"},{"key":"10.1002\/14651858.CD014769.pub2-BIB0082|cit82","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1016\/j.ejim.2017.10.008","article-title":"Association between statin exposure and venous thromboembolism risk in cancer patients. Data from the EDITH case-control study","volume":"46","author":"De Moreuil","year":"2017","journal-title":"European journal of internal medicine"},{"key":"10.1002\/14651858.CD014769.pub2-BIB0083|cit83","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"18","key":"10.1002\/14651858.CD014769.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1056\/NEJM200111013451811","article-title":"Choosing a parenteral anticoagulant agent","volume":"345","author":"Diuguid","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD014769.pub2-BIB0085|cit85","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/j.1538-7836.2004.00696.x","article-title":"HMG CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women","volume":"2","author":"Doggen","year":"2004","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014769.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.thromres.2017.08.001","article-title":"Statin use and venous thromboembolism in cancer: a large, active comparator, propensity score matched cohort study","volume":"158","author":"El-Refai","year":"2017","journal-title":"Thrombosis Research"},{"issue":"12","key":"10.1002\/14651858.CD014769.pub2-BIB0087|cit87","doi-asserted-by":"publisher","first-page":"e14805","DOI":"10.1111\/ctr.14805","article-title":"Postoperative statin therapy is not associated with reduced incidence of venous thromboembolic events following kidney transplantation","volume":"36","author":"Frasco","year":"2022","journal-title":"Clinical transplantation"},{"issue":"3","key":"10.1002\/14651858.CD014769.pub2-BIB0088|cit88","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.acvd.2015.11.007","article-title":"Statins and prevention of venous thromboembolism: myth or reality?","volume":"109","author":"Gaertner","year":"2016","journal-title":"Archives of Cardiovascular Diseases"},{"issue":"10","key":"10.1002\/14651858.CD014769.pub2-BIB0089|cit89","first-page":"664","article-title":"Statins: the drugs for the 21st century?","volume":"110","author":"Ginter","year":"2009","journal-title":"Bratislavske Lekarske Listy"},{"key":"10.1002\/14651858.CD014769.pub2-BIB0090|cit90","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2020"},{"issue":"9","key":"10.1002\/14651858.CD014769.pub2-BIB0091|cit91","doi-asserted-by":"publisher","first-page":"689","DOI":"10.7326\/0003-4819-132-9-200005020-00002","article-title":"Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen\/progestin Replacement Study","volume":"132","author":"Grady","year":"2000","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD014769.pub2-BIB0092|cit92","doi-asserted-by":"publisher","first-page":"e072715","DOI":"10.1136\/bmj-2022-072715","article-title":"Prevention of venous thromboembolism in patients with cancer","volume":"381","author":"Guntupalli","year":"2023","journal-title":"British Medical Association"},{"issue":"7650","key":"10.1002\/14651858.CD014769.pub2-BIB0093|cit93","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"12","key":"10.1002\/14651858.CD014769.pub2-BIB0094|cit94","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","article-title":"GRADE guidelines 6. Rating the quality of evidence - imprecision","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"8","key":"10.1002\/14651858.CD014769.pub2-BIB0095|cit95","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nrcardio.2015.83","article-title":"Epidemiology of venous thromboembolism","volume":"12","author":"Heit","year":"2015","journal-title":"Nature Reviews Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD014769.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11239-015-1311-6","article-title":"The epidemiology of venous thromboembolism","volume":"41","author":"Heit","year":"2016","journal-title":"Journal of Thrombosis and Thrombolysis"},{"issue":"25","key":"10.1002\/14651858.CD014769.pub2-BIB0097|cit97","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1161\/01.cir.0000019406.74017.b2","article-title":"Statin therapy, cardiovascular events, and total mortality in the heart and estrogen\/progestin replacement study (HERS)","volume":"105","author":"Herrington","year":"2002","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD014769.pub2-BIB0098|cit98","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017), Cochrane, 2017 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD014769.pub2-BIB0099|cit99","unstructured":"Higgins JP Li T Deeks JJ Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"3","key":"10.1002\/14651858.CD014769.pub2-BIB0100|cit100","doi-asserted-by":"publisher","first-page":"144","DOI":"10.5694\/j.1326-5377.2008.tb01947.x","article-title":"The incidence of venous thromboembolism: a prospective, community-based study in Perth, Western Australia","volume":"189","author":"Ho","year":"2008","journal-title":"Medical Journal of Australia"},{"issue":"9","key":"10.1002\/14651858.CD014769.pub2-BIB0101|cit101","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1001\/archinte.167.9.935","article-title":"Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom","volume":"167","author":"Huerta","year":"2007","journal-title":"Archives of Internal Medicine"},{"issue":"17","key":"10.1002\/14651858.CD014769.pub2-BIB0102|cit102","doi-asserted-by":"publisher","first-page":"e130","DOI":"10.3346\/jkms.2022.37.e130","article-title":"Incidence of venous thromboembolism: the 3rd Korean nationwide study","volume":"37","author":"Hwang","year":"2022","journal-title":"Journal of Korean Medical Science"},{"issue":"10","key":"10.1002\/14651858.CD014769.pub2-BIB0103|cit103","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1111\/jth.12698","article-title":"Thrombosis: a major contributor to the global disease burden","volume":"12","author":"ISTH Steering Committee for World Thrombosis Day","year":"2014","journal-title":"Journal of Thrombis and Haemostasis"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD014769.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1067\/mhj.2002.130300","article-title":"Structural mechanism for statin inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase","volume":"144","author":"Istvan","year":"2002","journal-title":"American Heart Journal"},{"issue":"3","key":"10.1002\/14651858.CD014769.pub2-BIB0105|cit105","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1093\/cvr\/cvab078","article-title":"Rosuvastatin for the prevention of venous thromboembolism: a pooled analysis of the HOPE-3 and JUPITER randomized controlled trials","volume":"118","author":"Joseph","year":"2022","journal-title":"Cardiovascular Research"},{"issue":"5","key":"10.1002\/14651858.CD014769.pub2-BIB0106|cit106","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1111\/j.1538-7836.2004.00658.x","article-title":"Effects of lipids and lipid-lowering therapy on hemostatic factors in patients with myocardial infarction","volume":"2","author":"Kaba","year":"2004","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014769.pub2-BIB0107|cit107","doi-asserted-by":"publisher","first-page":"103782","DOI":"10.1016\/j.critrevonc.2022.103782","article-title":"Venous thromboembolism in cancer and cancer immunotherapy","volume":"178","author":"Kacimi","year":"2022","journal-title":"Critical Reviews in Oncology\/Hematology"},{"issue":"2","key":"10.1002\/14651858.CD014769.pub2-BIB0108|cit108","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1016\/S2352-3026(16)30184-3","article-title":"Statins and primary prevention of venous thromboembolism: a systematic review and meta-analysis","volume":"4","author":"Kunutsor","year":"2017","journal-title":"Lancet Haematology"},{"issue":"4","key":"10.1002\/14651858.CD014769.pub2-BIB0109|cit109","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/j.1472-8206.2004.00252.x","article-title":"Statins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospital-based case-control study","volume":"18","author":"Lacut","year":"2004","journal-title":"Fundamental and Clinical Pharmacology"},{"issue":"3","key":"10.1002\/14651858.CD014769.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.thromres.2007.10.014","article-title":"Differential associations between lipid-lowering drugs, statins and fibrates, and venous thromboembolism: role of drug induced homocysteinemia?","volume":"122","author":"Lacut","year":"2008","journal-title":"Thrombosis Research"},{"issue":"11","key":"10.1002\/14651858.CD014769.pub2-BIB0111|cit111","doi-asserted-by":"publisher","first-page":"e005862","DOI":"10.1136\/bmjopen-2014-005862","article-title":"The association of statin use with reduced incidence of venous thromboembolism: a population-based cohort study","volume":"4","author":"Lassila","year":"2014","journal-title":"BMJ Open"},{"issue":"12","key":"10.1002\/14651858.CD014769.pub2-BIB0112|cit112","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1160\/TH17-02-0134","article-title":"Incidence of venous thromboembolism in Asian populations: a systematic review","volume":"117","author":"Lee","year":"2017","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014769.pub2-BIB0113|cit113","unstructured":"Lefebvre C Glanville J Briscoe S Featherstone R Littlewood A Marshall C Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook"},{"issue":"12","key":"10.1002\/14651858.CD014769.pub2-BIB0114|cit114","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008203.pub3","article-title":"Statins for primary prevention of venous thromboembolism","author":"Li","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD014769.pub2-BIB0115|cit115","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010957.pub3","article-title":"Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of pulmonary embolism","author":"Li","year":"2023","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD014769.pub2-BIB0116|cit116","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1055\/s-0033-1343892","article-title":"Venous thrombosis associated with HMG-CoA reductase inhibitors","volume":"39","author":"Lippi","year":"2013","journal-title":"Seminars in Thrombosis and Hemostasis"},{"issue":"3","key":"10.1002\/14651858.CD014769.pub2-BIB0117|cit117","doi-asserted-by":"publisher","first-page":"A272","DOI":"10.1016\/j.jval.2013.03.1407","article-title":"Epidemiology and mortality of venous thromboembolism across patient populations: a systematic literature review","volume":"16","author":"Liu","year":"2013","journal-title":"Value in Health"},{"key":"10.1002\/14651858.CD014769.pub2-BIB0118|cit118","doi-asserted-by":"publisher","first-page":"927092","DOI":"10.3389\/fnut.2022.927092","article-title":"Biological actions, implications and cautions of statins therapy in COVID-19","volume":"9","author":"Liu","year":"2022","journal-title":"Frontiers in Nutrition"},{"issue":"5","key":"10.1002\/14651858.CD014769.pub2-BIB0119|cit119","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.thromres.2014.09.001","article-title":"Statins are associated with low risk of venous thromboembolism in patients with cancer: a prospective and observational cohort study","volume":"134","author":"L\u00f6tsch","year":"2014","journal-title":"Thrombosis research"},{"issue":"9841","key":"10.1002\/14651858.CD014769.pub2-BIB0120|cit120","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"issue":"10","key":"10.1002\/14651858.CD014769.pub2-BIB0121|cit121","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.numecd.2019.06.022","article-title":"Statins and risk of thromboembolism: a meta-regression to disentangle the efficacy-to-effectiveness gap using observational and trial evidence","volume":"29","author":"Miksza","year":"2019","journal-title":"Nutrition, Metabolism, and Cardiovascular Diseases"},{"key":"10.1002\/14651858.CD014769.pub2-BIB0122|cit122","doi-asserted-by":"publisher","first-page":"124610","DOI":"10.5402\/2011\/124610","article-title":"Venous thromboembolism: classification, risk factors, diagnosis, and management","volume":"2011","author":"Moheimani","year":"2011","journal-title":"ISRN Hematology"},{"issue":"18","key":"10.1002\/14651858.CD014769.pub2-BIB0123|cit123","doi-asserted-by":"publisher","first-page":"3188","DOI":"10.1182\/blood-2013-04-491845","article-title":"Antithrombotic actions of statins involve PECAM-1 signaling","volume":"122","author":"Moraes","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD014769.pub2-BIB0124|cit124","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.advms.2022.10.002","article-title":"Venous thromboembolism: Why is it still a significant health problem?","volume":"68","author":"Oleksiuk-B\u00f3jko","year":"2023","journal-title":"Adv Med Sci"},{"issue":"8","key":"10.1002\/14651858.CD014769.pub2-BIB0125|cit125","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1055\/s-0039-1687911","article-title":"Statin therapy to revert hypercoagulability and prevent venous thromboembolism: a narrative review","volume":"45","author":"Orsi","year":"2019","journal-title":"Seminars in Thrombosis and Hemostosis"},{"key":"10.1002\/14651858.CD014769.pub2-BIB0126|cit126","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD014769.pub2-BIB0127|cit127","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Available from training.cochrane.org\/handbook","author":"Page M","year":"2022"},{"issue":"5","key":"10.1002\/14651858.CD014769.pub2-BIB0128|cit128","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.thromres.2011.05.012","article-title":"Statins in the prevention of venous thromboembolism: a meta-analysis of observational studies","volume":"128","author":"Pai","year":"2011","journal-title":"Thrombosis Research"},{"issue":"1","key":"10.1002\/14651858.CD014769.pub2-BIB0129|cit129","doi-asserted-by":"publisher","first-page":"115","DOI":"10.5114\/aoms.2015.49216","article-title":"The influence of statin therapy on platelet activity markers in hyperlipidemic patients after ischemic stroke","volume":"11","author":"Pawelczyk","year":"2015","journal-title":"Archives of Medical Science"},{"issue":"10","key":"10.1002\/14651858.CD014769.pub2-BIB0130|cit130","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.medcli.2017.11.030","article-title":"Statins: pros and cons","volume":"150","author":"Pinal-Fernandez","year":"2018","journal-title":"Medicina cl\u00ednica"},{"issue":"9","key":"10.1002\/14651858.CD014769.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"e1001310","DOI":"10.1371\/journal.pmed.1001310","article-title":"Effect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trials","volume":"9","author":"Rahimi","year":"2012","journal-title":"PLOS Medicine"},{"issue":"12","key":"10.1002\/14651858.CD014769.pub2-BIB0132|cit132","doi-asserted-by":"publisher","first-page":"659","DOI":"10.5694\/j.1326-5377.2009.tb02629.x","article-title":"Duration of anticoagulant therapy for venous thromboembolism","volume":"190","author":"Raju","year":"2009","journal-title":"Medical Journal of Australia"},{"issue":"4","key":"10.1002\/14651858.CD014769.pub2-BIB0133|cit133","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/j.1538-7836.2008.03235.x","article-title":"HMG-CoA-reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis","volume":"7","author":"Ramcharan","year":"2009","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"4","key":"10.1002\/14651858.CD014769.pub2-BIB0134|cit134","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/cvm-2-4-165","article-title":"The role of dyslipidemia and statins in venous thromboembolism","volume":"2","author":"Ray","year":"2001","journal-title":"Current Controlled Trials in Cardiovascular Medicine"},{"issue":"11","key":"10.1002\/14651858.CD014769.pub2-BIB0135|cit135","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1001\/archinte.161.11.1405","article-title":"Use of statins and the subsequent development of deep vein thrombosis","volume":"161","author":"Ray","year":"2001","journal-title":"Archives of Internal Medicine"},{"issue":"5","key":"10.1002\/14651858.CD014769.pub2-BIB0136|cit136","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1097\/00063198-200309000-00007","article-title":"Dyslipidemia, statins, and venous thromboembolism: a potential risk factor and a potential treatment","volume":"9","author":"Ray","year":"2003","journal-title":"Current Opinion in Pulmonary Medicine"},{"key":"10.1002\/14651858.CD014769.pub2-BIB0137|cit137","unstructured":"Review Manager 5 (RevMan 5) The Cochrane Collaboration 2020"},{"key":"10.1002\/14651858.CD014769.pub2-BIB0138|cit138","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2019"},{"issue":"9841","key":"10.1002\/14651858.CD014769.pub2-BIB0139|cit139","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(12)61190-8","article-title":"Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial","volume":"380","author":"Ridker","year":"2012","journal-title":"Lancet"},{"issue":"8","key":"10.1002\/14651858.CD014769.pub2-BIB0140|cit140","first-page":"e295","article-title":"Statin use and bleeding risk during vitamin K antagonist treatment for venous thromboembolism: a multicenter retrospective cohort study","volume":"100","author":"Riva","year":"2015","journal-title":"Haematologica"},{"issue":"4","key":"10.1002\/14651858.CD014769.pub2-BIB0141|cit141","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s11239-012-0687-9","article-title":"Statins, inflammation and deep vein thrombosis: a systematic review","volume":"33","author":"Rodriguez","year":"2012","journal-title":"Journal of Thrombosis and Thrombolysis"},{"key":"10.1002\/14651858.CD014769.pub2-BIB0142|cit142","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"1","key":"10.1002\/14651858.CD014769.pub2-BIB0143|cit143","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s11239-013-1015-8","article-title":"Statins, aspirin and risk of venous thromboembolic events in breast cancer patients","volume":"38","author":"Shai","year":"2014","journal-title":"Journal of thrombosis and thrombolysis"},{"key":"10.1002\/14651858.CD014769.pub2-BIB0144|cit144","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.thromres.2019.11.003","article-title":"Initiation of statins and risk of venous thromboembolism: population-based matched cohort study","volume":"184","author":"Skajaa","year":"2019","journal-title":"Thrombosis Research"},{"issue":"1","key":"10.1002\/14651858.CD014769.pub2-BIB0145|cit145","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1365-2125.2008.03308.x","article-title":"Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials","volume":"67","author":"Smeeth","year":"2009","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"9","key":"10.1002\/14651858.CD014769.pub2-BIB0146|cit146","first-page":"1031","article-title":"Drug class effects: definitions and practical applications","volume":"21","author":"Soares","year":"2002","journal-title":"Revista Portuguesa de Cardiologia"},{"key":"10.1002\/14651858.CD014769.pub2-BIB0147|cit147","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2147\/VHRM.S132556","article-title":"Direct oral anticoagulants for treatment and prevention of venous thromboembolism in cancer patients","volume":"15","author":"Song","year":"2019","journal-title":"Vascular Health and Risk Management"},{"issue":"10","key":"10.1002\/14651858.CD014769.pub2-BIB0148|cit148","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1093\/eurheartj\/ehp556","article-title":"Statins, fibrates, and venous thromboembolism: a meta-analysis","volume":"31","author":"Squizzato","year":"2010","journal-title":"European Heart Journal"},{"issue":"2","key":"10.1002\/14651858.CD014769.pub2-BIB0149|cit149","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s11739-014-1168-2","article-title":"Under-reporting of venous and arterial thrombotic events in randomized clinical trials: a meta-analysis","volume":"10","author":"Stuijver","year":"2015","journal-title":"Internal and Emergency Medicine"},{"issue":"4","key":"10.1002\/14651858.CD014769.pub2-BIB0150|cit150","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/j.1538-7836.2009.03279.x","article-title":"Arterial cardiovascular events, statins, low-dose aspirin and subsequent risk of venous thromboembolism: a population-based case-control study","volume":"7","author":"S\u00f8rensen","year":"2009","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"9","key":"10.1002\/14651858.CD014769.pub2-BIB0151|cit151","doi-asserted-by":"publisher","first-page":"832.e13","DOI":"10.1016\/j.amjmed.2013.02.024","article-title":"Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE study cohort","volume":"126","author":"Tagalakis","year":"2013","journal-title":"American Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD014769.pub2-BIB0152|cit152","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004816.pub5","article-title":"Statins for the primary prevention of cardiovascular disease","author":"Taylor","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD014769.pub2-BIB0153|cit153","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1002\/pds.4020","article-title":"Statin use and the risk of developing diabetes: a network meta-analysis","volume":"25","author":"Thakker","year":"2016","journal-title":"Pharmacoepidemiology and Drug Safety"},{"key":"10.1002\/14651858.CD014769.pub2-BIB0154|cit154","volume-title":"User Manual for Trial Sequential Analysis (TSA)","author":"Thorlund","year":"2011"},{"issue":"2","key":"10.1002\/14651858.CD014769.pub2-BIB0155|cit155","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1161\/01.ATV.0000151647.14923.ec","article-title":"Statins and blood coagulation","volume":"25","author":"Undas","year":"2005","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"issue":"2","key":"10.1002\/14651858.CD014769.pub2-BIB0156|cit156","doi-asserted-by":"publisher","first-page":"16208","DOI":"10.20452\/pamw.16208","article-title":"Statins in prevention of thromboembolic events: from seminal studies to recent advances","volume":"132","author":"Undas","year":"2022","journal-title":"Polish Archives of Internal Medicine"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014769.pub2-BIB0157|cit157","doi-asserted-by":"publisher","first-page":"S207","DOI":"10.21037\/cdt.2017.09.12","article-title":"Statins as a preventative therapy for venous thromboembolism","volume":"7","author":"Wallace","year":"2017","journal-title":"Cardiovascular Diagnosis and Therapy"},{"key":"10.1002\/14651858.CD014769.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1471-2288-9-86","article-title":"Estimating required information size by quantifying diversity in random-effects model meta-analyses","volume":"9","author":"Wetterslev","year":"2009","journal-title":"BMC Medical Research Methodology"},{"issue":"1","key":"10.1002\/14651858.CD014769.pub2-BIB0159|cit159","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1046\/j.0306-5251.2001.01523.x","article-title":"Statins and the risk of idiopathic venous thromboembolism","volume":"53","author":"Yang","year":"2002","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD014769.pub2-BIB0160|cit160","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.atherosclerosis.2018.02.035","article-title":"Is the lower risk of venous thromboembolism with statins related to low-density-lipoprotein reduction? A network meta-analysis and meta-regression of randomised controlled trials","volume":"271","author":"Zaccardi","year":"2018","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1002\/14651858.CD014769.pub2-BIB0161|cit161","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014769","article-title":"Statins for the prevention of primary venous thromboembolism","author":"Zhang","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T08:19:35Z","timestamp":1774858775000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD014769.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,11,5]]},"references-count":161,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd014769.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,5]]}}}